Vident Partners provides vetted rheumatology expert witnesses for cases involving missed giant cell arteritis and vision loss, delayed diagnosis of inflammatory and autoimmune disease, methotrexate and biologic dosing errors, immunosuppression-related infection, septic arthritis, and disability and functional capacity disputes. Request a referral today.
Find a Rheumatology Expert →Overview
Rheumatology litigation divides cleanly into two categories: failures of diagnosis, where an inflammatory or autoimmune process was attributed to something benign until irreversible damage occurred, and failures of drug management, where an immunosuppressive or cytotoxic regimen caused injury. Certification is a subspecialty of internal medicine through the American Board of Internal Medicine 1, and the American College of Rheumatology maintains the clinical practice guidelines that supply most of the benchmarks in these cases 2.
No rheumatologic condition produces more litigation per case than giant cell arteritis, because the injury is sudden, permanent, and preventable. In the United States the lifetime risk of developing GCA is approximately 1% for women and 0.5% for men, and current studies estimate the incidence of permanent vision loss at 8.2% of patients with GCA 3. The governing clinical principle is unambiguous and rarely survives a defense verdict when breached: given the risk of permanent vision loss, clinicians begin glucocorticoid therapy as soon as GCA is suspected, with temporal artery biopsy completed within two weeks of starting treatment 3. Two evidentiary features recur. First, the diagnostic sensitivity of temporal artery biopsy is approximately 77%, and skip lesions produce false-negative results in up to 44% of patients — so a negative biopsy does not exonerate a delayed treatment decision 3. Second, 40% to 60% of patients with GCA also have polymyalgia rheumatica, and 16% to 21% of patients with polymyalgia rheumatica have GCA, which makes a documented PMR diagnosis powerful evidence that GCA should have been on the differential 3.
Septic arthritis misdiagnosed as a gout or rheumatoid flare is a recurring and high-damages fact pattern, because the joint is destroyed within days. Other frequent claims include delayed recognition of lupus nephritis, ANCA-associated vasculitis presenting as renal or pulmonary disease, and inflammatory back pain dismissed as mechanical for years. Rheumatologists are also retained on the non-malpractice side of the docket — in disability, workers' compensation, and long-term disability litigation, where the question is functional capacity and the objectivity of a condition such as fibromyalgia, and in toxic exposure matters where an autoimmune condition is attributed to a chemical or drug exposure. The NIAMS patient and clinician resources are frequently used to frame baseline disease natural history for a lay jury 5.
The incidence of permanent vision loss in giant cell arteritis is estimated at 8.2%, and the diagnostic sensitivity of temporal artery biopsy is only about 77% — with skip lesions producing false-negative results in up to 44% of patients, so a negative biopsy does not excuse a delay in starting glucocorticoids.
Case Types
Missed or delayed giant cell arteritis diagnosis resulting in permanent vision loss
Septic arthritis misdiagnosed as a gout or rheumatoid flare, with joint destruction
Methotrexate daily-instead-of-weekly dosing errors and monitoring failures
Opportunistic infection or tuberculosis reactivation after biologic therapy without screening
Delayed diagnosis of lupus nephritis or ANCA-associated vasculitis with organ loss
Corticosteroid complications including avascular necrosis and fragility fracture
Disability and functional capacity disputes involving inflammatory arthritis or fibromyalgia
Qualifications
Related Specialties
FAQ
The expert should hold ABIM subspecialty certification in Rheumatology, which requires prior Internal Medicine certification and an accredited fellowship, and should be actively managing patients on immunosuppressive therapy. Familiarity with the American College of Rheumatology guidelines in effect at the time of the care is important, as these guidelines are revised and an expert applying a later version retrospectively is vulnerable on cross.
These experts are retained in missed giant cell arteritis and vision loss cases, septic arthritis misdiagnoses, methotrexate and biologic medication errors, immunosuppression-related infections, delayed diagnosis of lupus or vasculitis with organ damage, and steroid complication claims. They also appear in disability, workers' compensation, and toxic exposure matters where autoimmune disease and functional capacity are at issue.
No, and it is a frequent misunderstanding. The diagnostic sensitivity of temporal artery biopsy is approximately 77%, and skip lesions cause false-negative results in up to 44% of patients. The standard-of-care question is whether glucocorticoids were started when GCA was suspected — because treatment is not supposed to wait for the biopsy — and whether the biopsy was obtained within about two weeks of starting steroids so the histology remained interpretable.
Frequently more than one party. The prescribing rheumatologist, a covering physician who renewed the prescription, the dispensing pharmacist who did not flag a daily sig on a weekly drug, and the nursing or facility staff who administered it may all be implicated. These cases typically require a rheumatology expert on the prescribing standard and a pharmacy expert on dispensing and verification, and the electronic prescribing record is usually decisive.
It depends on where the alleged failure occurred. If the claim is that a primary care physician failed to recognize a red-flag presentation and refer, an internist or family physician can address that duty. If the claim concerns the selection, dosing, or monitoring of disease-modifying or biologic therapy, courts generally expect a rheumatologist. Many of these cases involve both a referral failure and a subsequent management failure, and are best staffed with an expert for each.
In general, expert fees are determined by the expert themselves, based on a variety of criteria. Among those criteria are professional experience, forensic and testimony experience, relevant certifications, case-type specialization, and publications. Vident does have some influence over expert fees by comparing experts within a specialty, but ultimately it is a personal decision by the expert.
Related Insights
Over the past several years I have reviewed medical charts for both insurance companies and pain clinics to determine if what has been recorded makes good medical sense and shows an appropriate level...
Research BriefingFentanyl, a synthetic opioid, was first developed by Dr. Paul Janssen in the 1960s. From its inception, it was designed to be fast-acting, highly potent, and more readily synthesized than naturally oc...
Case AnalysisI was not familiar with this term before reading Hill v. Emergency Medicine of Idaho and Dr. Stuart Clive (3/27/25). Perhaps the court wasn’t either, because the opinion repeatedly puts “hindsight...
Sources
Vident Partners connects attorneys with qualified rheumatology expert witnesses. Complimentary consultation, 24-hour turnaround, no obligation.
Request an Expert →